DIPEPTIDYL PEPTIDASE - 4 INHIBITORS IN REGALING TYPE 2 DIABETES MELLITUS: A REVIEW

Abstract

A novel class of antidiabetic drugs which were explicated for the treatment of type 2 diabetes mellitus is the dipeptidyl peptidase (DPP) - 4 inhibitors. The DPP-4 inhibitors foreclose the metabolism of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide, advancing the combination and discharge of insulin when blood levels of glucose are elevated. There are more or less divergences between them as far as their absorption, distribution, metabolism & excretion and additionally in their strength and span of activity. However, their efficaciousness seems to be alike. They enhance glycemic control, decreasing both fasting and postprandial glucose levels to bring down HbA1c levels, without weight gain. The available DPP-4 inhibitors for the treatment of type 2 diabetes are saxagliptin, sitagliptin linagliptin, alogliptin, and vildagliptin.